Experimental CAR-T therapy targets tough autoimmune blood diseases
NCT ID NCT07441525
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment called RD06-05, a type of CAR-T cell therapy, in 27 adults with autoimmune blood diseases like immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), or Evans syndrome. The therapy aims to control the disease by targeting and reducing harmful immune cells. Participants receive one of two dose levels, and the study monitors safety, side effects, and how well the treatment works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
RECRUITINGWuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test predict clot risk in antiphospholipid syndrome?
- Engineered immune cells take aim at stubborn blood disorder
- Cheap drug combo may tame tough anemia
- Scientists hunt for genetic roots of rare childhood blood disorder
- New study aims to unlock the secrets of Children's rare blood diseases
- Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial